Insulet (NASDAQ:PODD) Price Target Raised to $428.00

Insulet (NASDAQ:PODD) had its price target boosted by Canaccord Genuity Group from $399.00 to $428.00 in a research report released on Friday morning,Benzinga reports. Canaccord Genuity Group currently has a buy rating on the medical instruments supplier’s stock.

PODD has been the topic of a number of other research reports. Rothschild & Co Redburn upped their price target on shares of Insulet from $350.00 to $370.00 and gave the company a “buy” rating in a research note on Friday, October 3rd. The Goldman Sachs Group decreased their target price on shares of Insulet from $399.00 to $375.00 and set a “buy” rating on the stock in a research report on Wednesday, October 1st. Raymond James Financial raised their price target on Insulet from $360.00 to $366.00 and gave the stock an “outperform” rating in a research report on Friday. Wolfe Research increased their price objective on shares of Insulet from $350.00 to $375.00 and gave the stock an “outperform” rating in a research note on Friday. Finally, UBS Group boosted their target price on shares of Insulet from $320.00 to $355.00 and gave the company a “neutral” rating in a research report on Friday. One equities research analyst has rated the stock with a Strong Buy rating, nineteen have given a Buy rating and three have assigned a Hold rating to the company. Based on data from MarketBeat.com, Insulet has an average rating of “Moderate Buy” and an average price target of $371.38.

Insulet Stock Down 1.1%

PODD opened at $319.82 on Friday. The stock’s fifty day simple moving average is $325.06 and its 200 day simple moving average is $310.30. Insulet has a 1-year low of $230.05 and a 1-year high of $353.50. The stock has a market cap of $22.51 billion, a PE ratio of 97.21, a price-to-earnings-growth ratio of 2.64 and a beta of 1.39. The company has a current ratio of 2.26, a quick ratio of 1.81 and a debt-to-equity ratio of 0.64.

Insulet (NASDAQ:PODD) last released its quarterly earnings data on Thursday, November 6th. The medical instruments supplier reported $1.24 EPS for the quarter, beating the consensus estimate of $1.13 by $0.11. The firm had revenue of $521.70 million for the quarter, compared to the consensus estimate of $678.70 million. Insulet had a net margin of 10.01% and a return on equity of 23.78%. The company’s quarterly revenue was up 29.9% on a year-over-year basis. During the same period in the previous year, the company earned $1.08 earnings per share. Insulet has set its FY 2025 guidance at EPS. Q4 2025 guidance at EPS. As a group, research analysts expect that Insulet will post 3.92 earnings per share for the current year.

Insider Activity at Insulet

In other Insulet news, SVP Laetitia Cousin sold 797 shares of the firm’s stock in a transaction that occurred on Monday, September 8th. The shares were sold at an average price of $348.81, for a total value of $278,001.57. Following the sale, the senior vice president owned 3,890 shares in the company, valued at $1,356,870.90. This trade represents a 17.00% decrease in their ownership of the stock. The sale was disclosed in a filing with the SEC, which is available at this link. Also, SVP Prem Singh sold 687 shares of the company’s stock in a transaction on Monday, September 8th. The stock was sold at an average price of $347.49, for a total transaction of $238,725.63. Following the transaction, the senior vice president owned 3,456 shares of the company’s stock, valued at $1,200,925.44. This trade represents a 16.58% decrease in their ownership of the stock. Additional details regarding this sale are available in the official SEC disclosure. Insiders own 0.39% of the company’s stock.

Institutional Investors Weigh In On Insulet

Hedge funds and other institutional investors have recently bought and sold shares of the company. Larson Financial Group LLC raised its position in Insulet by 426.3% in the first quarter. Larson Financial Group LLC now owns 100 shares of the medical instruments supplier’s stock valued at $26,000 after purchasing an additional 81 shares during the last quarter. Zions Bancorporation National Association UT acquired a new position in shares of Insulet in the first quarter valued at approximately $26,000. SouthState Corp raised its holdings in Insulet by 253.3% in the 1st quarter. SouthState Corp now owns 106 shares of the medical instruments supplier’s stock valued at $28,000 after buying an additional 76 shares during the last quarter. True Wealth Design LLC boosted its position in Insulet by 288.0% during the 3rd quarter. True Wealth Design LLC now owns 97 shares of the medical instruments supplier’s stock worth $30,000 after buying an additional 72 shares during the period. Finally, Kozak & Associates Inc. bought a new stake in Insulet during the 2nd quarter worth approximately $32,000.

About Insulet

Insulet Corporation develops, manufactures, and sells insulin delivery systems for people with insulin-dependent diabetes. The company's Omnipod platform includes the Omnipod 5 Automated Insulin Delivery System (Omnipod 5) which includes a proprietary AID algorithm embedded in the Pod that integrates with a third-party continuous glucose monitor to obtain glucose values through wireless bluetooth communication; Omnipod DASH that features a bluetooth enabled Pod that is controlled by a smartphone-like Personal Diabetes Manager with a color touch screen user interface; and Omnipod GO, a standalone, wearable, insulin delivery system that provides a fixed rate of continuous rapid-acting insulin for 72 hours.